Feature

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief


 


Without clear answers, hospitals, doctors, and patients are left to their own devices, which can result in poor treatment and needless suffering.

Hospitals and other medical facilities have to decide what to do with newly hospitalized patients who normally take medical marijuana at home.

Some have a “don’t ask, don’t tell” approach, said Dr. Devinsky, who sometimes advises his patients to use it. Others ban its use and substitute opioids or other prescriptions.

Young adults, for instance, have had to stop taking cannabidiol compounds for their epilepsy because they’re in federally funded group homes, said Dr. Devinsky, the director of New York University’s Langone Comprehensive Epilepsy Center.

“These kids end up getting seizures again,” he said. “This whole situation has created a hodgepodge of insanity.”

Pages

Recommended Reading

Opioids linked to mortality in IBD
MDedge Internal Medicine
Abstract: Don't demonise prescription opioids
MDedge Internal Medicine
FDA advisors recommend lofexidine for opioid withdrawal
MDedge Internal Medicine
FDA recalls kratom products for salmonella contamination
MDedge Internal Medicine
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Internal Medicine
Sensitivity of vibration-based neuropathy detectors varies widely
MDedge Internal Medicine
CMS finalizes measures to help combat opioid crisis
MDedge Internal Medicine
Epilepsy upped risk of unnatural death
MDedge Internal Medicine
Life and health are not even across the U.S.
MDedge Internal Medicine
CDC: Marijuana use may spur industries to rethink current policies
MDedge Internal Medicine